News & Updates

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide are both effective at lowering haemoglobin A1c (A1c) among veterans with type 2 diabetes mellitus (T2DM), reports a recent study, which provides insights into key considerations for this population.

Early dipeptidyl peptidase 4 (DPP-4) inhibitor intensification delays insulin initiation in Chinese patients with type 2 diabetes (T2D), a cohort study in Hong Kong has shown.

Once-weekly insulin icodec with a dosing guide app is better than once-daily (OD) basal insulin analogues at reducing glycated haemoglobin (HbA1c) and improving treatment satisfaction and compliance in patients with type 2 diabetes (T2D), a study has shown. In addition, hypoglycaemia rates were low and similar between treatment groups.

Once weekly injection of semaglutide causes weight loss in obese patients with heart failure with preserved ejection fraction (HFpEF), with positive shifts in symptoms and improvements in physical limitations in the STEP-HFpEF trial presented at ESC 2023.

Individuals with type 2 diabetes (T2D) who regularly consume ultraprocessed foods (UPF), regardless of diet quality, appear to have reduced survival and increased cardiovascular disease (CVD) mortality rate, suggests a recent study.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in significant weight loss in patients with obesity or overweight without diabetes, a study has shown. In addition, the best GLP-1RA agent appears to be semaglutide, showing superior efficacy and low-to-moderate risk of side effects.